PEG IFN- -2b plus ribavirin worth its cost in chronic hepatitis C

Author：  

Publisher： Adis International

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1379, 2003-01, pp. : 6-6

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

IFN- -2b + ribavirin more cost effective in hepatitis C

By  

Inpharma, Vol. 1, Iss. 1307, 2001-01 ,pp. : 6-6

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Peginterferon -2a Plus Ribavirin versus Interferon -2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C

By Sullivan S.D.  

PharmacoEconomics, Vol. 22, Iss. 4, 2004-01 ,pp. : 257-265

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Peginterferon -2a Plus Ribavirin versus Interferon -2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C

By Arguedas M.  

PharmacoEconomics, Vol. 22, Iss. 7, 2004-01 ,pp. : 477-479

Adis International

Access to resources Recommend Favorite

Interferon- -2b Plus Ribavirin: A Review of its Use in the Management of Chronic Hepatitis C

By Scott L.J.   Perry C.M.  

Drugs, Vol. 62, Iss. 3, 2002-01 ,pp. : 507-556

Adis International

Access to resources Recommend Favorite

Cost Effectiveness of Peginterferon -2a Plus Ribavirin versus Interferon -2b Plus Ribavirin as Initial Therapy for Treatment-Naive Chronic Hepatitis C. The Authors' Reply

By Sullivan S.D.  

PharmacoEconomics, Vol. 22, Iss. 7, 2004-01 ,pp. : 478-479

Adis International

Access to resources Recommend Favorite